# MADRIGAL PHARMACEUTICALS, INC. (MDGL) MD&A by fiscal year

Verbatim Item 7 Management's Discussion and Analysis sections from MADRIGAL PHARMACEUTICALS, INC.'s 10-K filings, one page per fiscal year. Extracted from SEC filings with the same bounded parser for every year. Filer text, not grepcent analysis or investment advice.

- [FY 2025 MD&A](/company/MDGL/mda/fy2025/): filed 2026-02-19; accession 0001628280-26-009514 (https://www.sec.gov/Archives/edgar/data/1157601/000162828026009514/mdgl-20251231.htm); latest 10-K
- [FY 2024 MD&A](/company/MDGL/mda/fy2024/): filed 2025-02-26; accession 0001628280-25-007980 (https://www.sec.gov/Archives/edgar/data/1157601/000162828025007980/mdgl-20241231.htm)
- [FY 2023 MD&A](/company/MDGL/mda/fy2023/): filed 2024-02-28; accession 0001628280-24-007376 (https://www.sec.gov/Archives/edgar/data/1157601/000162828024007376/mdgl-20231231.htm)
- [FY 2022 MD&A](/company/MDGL/mda/fy2022/): filed 2023-02-23; accession 0001193125-23-045575 (https://www.sec.gov/Archives/edgar/data/1157601/000119312523045575/d437449d10k.htm)
- [FY 2021 MD&A](/company/MDGL/mda/fy2021/): filed 2022-02-24; accession 0001193125-22-051569 (https://www.sec.gov/Archives/edgar/data/1157601/000119312522051569/d243442d10k.htm)

Back to /company/MDGL/